A morphologic study of the airway structure abnormalities in patients with asthma by high-resolution computed tomography

Dan Wang*, Jian Luo*, Wen Du, Lan-Lan Zhang, Li-Xiu He, Chun-Tao Liu

Department of Respiratory and Critical Care Medicine, West China School of Medicine and West China Hospital, Sichuan University, Chengdu 610041, China

Contributions: (I) Conception and design: D Wang, CT Liu; (II) Administrative support: CT Liu; (III) Provision of study materials or patients: D Wang, J Luo; (IV) Collection and assembly of data: D Wang, J Luo, W Du, LX He; (V) Data analysis and interpretation: D Wang, J Luo, LL Zhang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

*These authors contributed equally to this work.

Correspondence to: Chun-Tao Liu. NO. 37 Guoxue Alley, Chengdu 610041, China. Email: taosen666@vip.163.com.

Background: Airway structure changes, termed as airway remodeling, are common in asthma patients due to chronic inflammation, which can be assessed by high-resolution computed tomography (HRCT). Considering the controversial conclusions in the correlation of morphologic abnormalities with clinical feature and outcome, we aimed to further specify and evaluate the structural abnormalities of Chinese asthmatics by HRCT.

Methods: From August 2012 to February 2015, outpatients with asthma were recruited consecutively in the Asthma Center of West China Hospital, Sichuan University. Standard HRCT and pulmonary function test (PFT) were performed to collect information of bronchial wall thickening, bronchial dilatation, mucus impaction, emphysema, mosaic perfusion, atelectasis, and spirometric parameters. We reported the incidence of each structural abnormality in HRCT and compared it among different asthmatic severities.

Results: A total of 123 asthmatics were enrolled, among which 84 (68.3%) were female and 39 (31.7%) were male. At least one structural abnormality was detected by HRCT in 85.4% asthmatics, and the incidence of bronchial wall thickening, bronchial dilatation, mucus impaction, emphysema, mosaic perfusion, and atelectasis was 57.7%, 51.2%, 22%, 24.4%, 5.7% and 1.6%, respectively. The incidences of bronchial wall thickening, bronchial dilation and emphysema were significantly increased by asthma severity (P<0.05), while incidences of mucus impaction (26/27, 96.30%), mosaic perfusion (6/7, 85.71%) and atelectasis (2/2, 100%) were mainly found in severe asthma. We found a longer asthma history (28.13±18.55 years, P<0.001, P=0.003), older age (51.30±10.70 years, P=0.022, P=0.006) and lower predicted percentage of forced expiratory volume in one second (FEV₁) (41.97±15.19, P<0.001, P<0.001) and ratio of forced expiratory volume to forced vital capacity (FEV₁/FVC) (48.01±9.55, P<0.001, P<0.001) in patients with severe bronchial dilatation compared with those in none and mild bronchial dilation. A negative correlation was also found between the extent of bronchial dilation and FEV₁% as well as FEV₁/FVC (r=-0.359, P=0.004; r=-0.266, P=0.035, respectively).

Conclusions: The incidences of structural abnormalities detected by HRCT are fairly high in Chinese asthma populations, especially the bronchial wall thickening and bronchial dilatation, which are significantly increased in severe asthma, and are potential risk factors of pulmonary function decline in asthmatics.

Keywords: Bronchial asthma; high-resolution computed tomography (HRCT); airway remodeling; bronchiectasis

Submitted May 05, 2016. Accepted for publication Aug 08, 2016.
doi: 10.21037/jtd.2016.09.36
View this article at: http://dx.doi.org/10.21037/jtd.2016.09.36
Introduction

Bronchial asthma is a common chronic disease worldwide affecting 1% to 18% of the population in different countries (1), and a recent epidemiologic study reported that the prevalence of asthma in China was 0.5% to 5% with an increasing tendency (2). Chronic airway inflammation is the fundamental characteristic and mechanism in the development of asthma (1), in which multiple inflammatory cells were recruited and activated to release various inflammatory mediators, thus resulting in airway hyperresponsiveness, bronchial constriction and airway obstruction (3,4). Moreover, it has been demonstrated that persistent airway inflammation may further induce airway remodeling, which consists of structural changes in airway wall including airway wall inflammation and edema, subepithelial fibrosis, hypertrophy/hyperplasty of the smooth muscle cells, mucus gland hyperplasia, and angiogenesis (3-7). It is believed that airway remodeling is the consequence of airway damage and repair imbalance. Meanwhile, studies also demonstrated that airway remodeling could accelerate lung function decline, which may lead to fixed airway obstruction and reduced responsiveness to inhaled corticosteroids and bronchodilators (6,7).

The diagnosis of asthma, recommended by the 2014 Global Initiative for Asthma (GINA), is initially identified by the characteristic pattern and detailed history of variable respiratory symptoms, and finally documented by the reversible expiratory airflow limitation via spirometry or pulmonary function test (PFT) (1). Although the conventional PFT could provide average measurement of lung function, it cannot identify precise location and extent of airway abnormalities (8). Furthermore, for a long time asthma is speculated to be more of a functional disease than a structural disease, which is distinct from chronic obstructive pulmonary disease (COPD), and airway structure abnormalities are indeed rarely found by chest film in asthmatics. However, in recent years, it has been recognized that airway remodeling is one of the important pathological abnormalities in patients with asthma and could lead to airway morphological changes, and an increasing number of studies have focused on the use of high-resolution computed tomography (HRCT) to evaluate the airway structure changes (8-15). It was reported that HRCT could be used to quantify static and dynamic changes in multiple independent airways as small as 1 mm (8), thus making it possible to study the subtle structure changes in the airways of asthma patients. In addition, some in vivo researches have also been carried out to assess the effect of new therapies on airway remodeling by HRCT, which are not possible using conventional spirometry and histological examinations.

Several parameters including bronchial wall thickening, bronchial dilatation, mucus impaction, emphysema, mosaic perfusion on inspiratory images, and atelectasis have been reported in measuring airway structure abnormalities by HRCT (7,9-13). It was reported that the overall incidence of abnormalities in HRCT was as high as 72% in asthma patients (14,15). However, the incidence of individual abnormality varied in different studies, and the exact relationship between airway structure changes and asthma severities did not reach a consensus. Paganin and colleagues compared 57 adult chronic asthmatics of variable severities with ten normal subjects, and found that the incidence of bronchial wall thickening, bronchial dilatation, mucus impaction, emphysema, and atelectasis was 15.7%, 64.9%, 21.1%, 17.5%, and 12.3% respectively. However, they did not find the relationship between HRCT abnormalities and disease severities (14). In the study by Harmanç and colleagues (15), the incidence of bronchial wall thickening, bronchial dilatation, mucus impaction, and emphysema was reported as 67.9%, 9.3%, 1.8%, and 7.9% respectively, but they found that bronchial wall thickening, bronchial dilatation, and mucus impaction were all correlated positively with asthma severity while negatively with forced expiratory volume in one second (FEV1), which were further demonstrated by Park and Nakano (9,10). A study in China analyzed retrospectively the abnormalities of 28 asthma patients by HRCT, and the results showed a positive rate of 71.4%, of which bronchial wall thickening was detected in 15 cases (53.6%), while bronchial dilatation was in 6 cases (21.4%), and mosaic pattern was in 3 cases (11.8%) (16). However, the study didn’t analyze the relationship of structural abnormalities in HRCT with clinical feature.

During recent decades, the novel and precise technique of three-dimensional (3D) HRCT has developed as the stimulation of 3D models, which makes the measurements of structures of small airways possible and reliable, thus enabling the development of various lung models (17-20). Although 3D acquisition together with automatic analysis is time saving and is widely accepted as an optimal standard, in the study of airway morphometric characteristics in patients with asthma, the main structural features were reported to be identical with those found in HRCT alone, including bronchial wall thickness and emphysema (21-23). Furthermore, 3D is more likely to be regarded as a post-
processing method, because changes visualized in two-dimension (2D) projections were demonstrated to correspond to the airway flow limitations well (24). The 3D technique has additional advantages such as clearer imaging and more accurate measurement, but conventional HRCT contains cost-effective merits including wide-spread applications and availabilities in developing countries, and are indeed of clinical implications but not outdated as reported in recent studies using HRCT to evaluate air-trapping, airway narrowing and closure, and airway wall thickness (25-27). Hence, HRCT itself, regardless of 2D or 3D, should be considered as an independent methodology in assessing diseases.

Therefore, considering the controversial conclusions in the correlation of morphologic abnormalities with clinical features and outcomes, our study aimed to further specify and evaluate the structural abnormalities of Chinese asthmatics in HRCT.

**Methods**

**Objects**

From August 2012 to February 2015, outpatients with asthma were recruited in the Asthma Center of West China Hospital, Sichuan University. The diagnosis of asthma was established according to the diagnostic criteria recommended by the Chinese Thoracic Society including typical asthmatic symptoms such as recurrent wheeze, breathlessness, chest tightness and cough when exposed to allergens, which are usually alleviated spontaneously or after medication, and reversible airflow limitation and airway hyperresponsiveness documented by positive bronchial provocation test or bronchodilator reversibility test. Patients were excluded if they met one of the following criteria: (I) age <18 years old; (II) concomitant diseases such as but not limited to COPD, bronchiectasis, cystic fibrosis, allergic bronchopulmonary aspergillosis, tuberculosis, pneumonia, or sarcoidosis; (III) unwillingness or contraindications to perform HRCT and diagnostic criteria were used, and corresponding data was rechecked until the consistency test reached a Kappa of at least 75%. Bronchial wall thickening was assessed at a window level of −450 HU and a window width of 1,500 HU, while other structural abnormalities were viewed at a window level of −700 HU and a window width of 1,500 HU (28-32).

**Assessment of bronchial wall thickening**

Under a magnification of ×5, bronchial wall thickening was measured manually in all bronchi (3rd-5th generations) with more than 3/4 airway wall could be completely and clearly identified in a cross section in each slice of the inspiratory scans by electronic calipers. Bronchial wall thickening was further graded by severity as none (<1 mm), mild (1 to 2 mm), moderate (2 to 3 mm), and severe (≥3 mm), which are illustrated in Figure 1 (15,33).

**Assessment of bronchial dilation**

Bronchial dilation was considered if the internal diameter of any bronchi was greater than that of the adjacent pulmonary artery, the bronchial lumina (distal to bifurcation) had a lack of tapering and was greater than 2 cm, or if the peripheral airways (within 1 cm of the costal pleura) was visible (Figure 2) (15,28,31,32). Bronchial dilation were divided into three types according to the morphology of bronchii: (I) cylindric bronchial dilation, defined as the lack of bronchial tapering or the presence of smooth bronchial dilatation, and bronchial lumen greater than that of the accompanying pulmonary artery (Figure 2A,B); (II) varicoe bronchial dilation, identified when irregular or beaded dilatation of the bronchus were recognized (Figure 2B,C); and (III) cystic bronchial dilation, diagnosed by presence of...
Based on the established computed tomography (CT) criteria (35-37), the extent of bronchial dilation was scored as follows: grade 0 = no disease; grade 1 = localized bronchiectasis affecting one or part of one bronchopulmonary segment (localized); grade 2 = bronchiectasis in more than one bronchopulmonary segment (extensive); and grade 3 = generalized cystic bronchiectasis. Each of six lobes was scored and the lingular lobe was regarded as a separate lobe. We also classified bronchial dilation by severity as none (absence of bronchial dilation), mild (cylindric) and severe (varicose and cystic) bronchial dilation.

**Assessment of mucus impactions**

For dilated bronchi, mucus impactions were recognized as segmentally distributed densities, which were greater than the adjacent pulmonary arteries in diameter and were in beaded, gloved-finger like and nodular or oval shapes on a few consecutive scans; while for nondilated bronchi, they were presented as opacities in which normal-sized bronchial lumen was completely or partially filled forming the “tree-in-mud” pattern (15,33,38) (Figure 2C).

**Assessment of emphysema**

Different types of emphysema could be displayed independently or simultaneously, which included centrilobular, panlobular, paraseptal emphysema or irregular (paracatricial) emphysema (15,31-33,38) (Figure 3A). Centrilobular emphysema was defined as focal areas of low attenuation up to 1 cm in diameter within a homogeneous background of lung parenchyma. Panlobular emphysema was considered as large and extensive areas of uniformly low attenuation associated with a reduction in size of pulmonary

---

**Figure 1** Measurement of bronchial wall thickening in chest HRCT. HRCT manifestations of (A) normal bronchial wall (0.8 mm) from a patient with a one-year history of asthma and FEV₁% of 88% and FEV₁/FVC of 70%, (B) mild bronchial wall thickening (1.3 mm) retrieved from a patient with asthma for one year and FEV₁% of 56% and FEV₁/FVC of 48%, and (C) moderate bronchial wall thickening (2.2 mm) in a patient with asthma for 19 years and FEV₁% of 75% and FEV₁/FVC of 84%. FEV₁%, predicted percentage of forced expiratory volume in one second; FEV₁/FVC, ratio of forced expiratory volume in one second to forced vital capacity; HRCT, high-resolution computed tomography.
Figure 2 Assessment of bronchial dilation and mucus impaction in chest HRCT. HRCT manifestations of (A) cylindric bronchial dilation with “arrows” indicating lack of tapering greater 2 cm distal to bifurcation, and “arrowhead” referring visibility of peripheral airways, (B) varicose bronchial dilation (arrow) and mucus impactions (arrowhead), and (C) varicose bronchial dilation (arrow) and mucus impactions (arrowhead). FEV1%, predicted percentage of forced expiratory volume in one second; FEV1/FVC, ratio of forced expiratory volume in one second to force vital capacity; HRCT, high-resolution computed tomography.

Assessment of mosaic lung attenuation and atelectasis
Mosaic lung attenuation was defined as the presence of areas of variable lung attenuation on thin-section CT scans (28) (Figure 3B), while atelectasis was defined as one or more of the lung or lung capacity or air content being reduced (Figure 3C).

Pulmonary function testing
PFT was performed within the same week as the HRCT scans using plethysmography system (MastersScreen, Jäger, Germany). In accordance with the standard operation procedures recommended by the American Thoracic Society (ATS), spirometric data was recorded before inhalation of glucocorticoids or bronchodilators, and all enrolled patients were classified into three groups on the basis of predicted percentage of forced expiratory volume in one second (FEV1%) (mild, FEV1% ≥80%; moderate, 60%≤ FEV1 <80%; and severe, FEV1% <60%) along with daytime symptoms, night waking, and activity limitation due to asthma recommended by National Asthma Education and Prevention Program (NAEPP) (39).

Statistical analysis
An independent statistician, who was also blinded to the diagnosis and clinical findings of patients, conducted the statistical analysis by SPSS Statistics version 19.0 (Copyright © SPSS Inc., 1989–2007).

Dichotomous variables were reported as frequency and proportion, while continuous variables were showed as mean and standard derivation (SD). One-way analysis of variance (ANOVA) or Kruskal-Wallis Test was used to compare the age, body mass index (BMI), duration of disease, and FEV1% among different severities of asthma and bronchial dilation. Pearson Chi-Square or Fisher’s Exact Test was applied to analyze the significance of gender and different airway structural abnormalities among different groups of asthma. Clinical characteristics among different bronchial dilation severities and correlations between extent of bronchial dilation and PFT were analyzed by Games-Howell and Spearman’s correlation analyses, respectively. A P value of less than 0.05 was considered to be significant.

Results
A total of 123 asthmatics were enrolled, among which 84 (68.3%) were female and 39 (31.7%) were male, and 20 patients (16.3%) were smokers or ex-smokers. On the basis of FEV1%, all enrolled patients were classified into mild (n=30), moderate (n=33) and severe (n=60) asthma, and the results showed that patients with severe asthma were significantly older (48.25±11.71, P=0.019) and had experienced longer duration of asthma (21.20±16.33, P=0.007), but there were no significant differences in smoking history and BMI among the three groups. The detailed baseline characteristics of all enrolled patients were summarized in Table 1.

In our study, at least one HRCT structural abnormality was detected in 85.4% of the patients, and the incidence...
Table 1 Baseline characteristics of enrolled asthmatic patients

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Mild asthma (n=30)</th>
<th>Moderate asthma (n=33)</th>
<th>Severe asthma (n=60)</th>
<th>P (ANOVA)</th>
<th>P (mild vs. moderate)</th>
<th>P (mild vs. severe)</th>
<th>P (moderate vs. severe)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (female/male)</td>
<td>21/9</td>
<td>24/9</td>
<td>39/21</td>
<td>0.726</td>
<td>0.811</td>
<td>0.635</td>
<td>0.446</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>23.41±3.53</td>
<td>23.87±3.77</td>
<td>23.77±3.23</td>
<td>0.856</td>
<td>0.621</td>
<td>0.633</td>
<td>0.892</td>
</tr>
<tr>
<td>Age (yrs)</td>
<td>41.33±10.67</td>
<td>43.15±13.03</td>
<td>48.25±11.71</td>
<td>0.019</td>
<td>0.549</td>
<td>0.008</td>
<td>0.057</td>
</tr>
<tr>
<td>Disease duration (yrs)</td>
<td>13.17±15.25</td>
<td>11.76±12.93</td>
<td>21.20±16.33</td>
<td>0.007</td>
<td>0.693</td>
<td>0.027</td>
<td>0.005</td>
</tr>
<tr>
<td>Smoking population (n)</td>
<td>6 (20.0%)</td>
<td>7 (21.2%)</td>
<td>7 (11.7%)</td>
<td>0.400</td>
<td>0.905</td>
<td>0.345</td>
<td>0.238</td>
</tr>
<tr>
<td>Smoking history (pack-year)</td>
<td>2.06±4.94</td>
<td>4.27±11.34</td>
<td>1.80±5.43</td>
<td>0.285</td>
<td>0.329</td>
<td>0.822</td>
<td>0.158</td>
</tr>
<tr>
<td>FEV₁ (% (%))</td>
<td>93.70±10.85</td>
<td>69.30±5.24</td>
<td>40.17±12.51</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FEV₁/FVC (%)</td>
<td>75.28±7.45</td>
<td>68.06±10.32</td>
<td>49.29±11.53</td>
<td>&lt;0.001</td>
<td>0.002</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

ANOVA, analysis of variance; BMI, body mass index; yrs, years; FEV₁, %, predicted percentage of forced expiratory volume in one second; FEV₁/FVC, ratio of forced expiratory volume in one second to forced vital capacity; HRCT, high-resolution computed tomography.
of bronchial wall thickening, bronchial dilatation, mucus impaction, emphysema, mosaic perfusion on inspiratory images, and atelectasis/Lobar collapse was 57.7%, 51.2%, 22%, 24.4%, 5.7% and 1.6%, respectively (Tables 2-4).

Table 2 The prevalence of bronchial wall thickening among different asthma severities

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Mild asthma, n (%)</th>
<th>Moderate asthma, n (%)</th>
<th>Severe asthma, n (%)</th>
<th>Total, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BWT*</td>
<td>9 (30.00)</td>
<td>15 (45.50)</td>
<td>47 (78.30)</td>
<td>71 (57.70)</td>
</tr>
<tr>
<td>Severity of BWT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild</td>
<td>8 (26.70)</td>
<td>12 (36.40)</td>
<td>31 (51.70)</td>
<td>51 (41.50)</td>
</tr>
<tr>
<td>Moderate</td>
<td>1 (3.30)</td>
<td>3 (9.10)</td>
<td>16 (26.70)</td>
<td>20 (16.30)</td>
</tr>
<tr>
<td>Severe</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
</tr>
</tbody>
</table>

* significant difference was found in prevalence of BWT among different asthma severity groups (P<0.05). BWT, bronchial wall thickening.

Table 3 The prevalence of bronchial dilation among different asthma severities

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Mild asthma, n (%)</th>
<th>Moderate asthma, n (%)</th>
<th>Severe asthma, n (%)</th>
<th>Total, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BD*</td>
<td>11 (36.70)</td>
<td>14 (42.40)</td>
<td>38 (63.30)</td>
<td>63 (51.20)</td>
</tr>
<tr>
<td>Types of BD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cylindric</td>
<td>11 (36.70)</td>
<td>13 (39.40)</td>
<td>16 (26.70)</td>
<td>40 (32.50)</td>
</tr>
<tr>
<td>Varicose</td>
<td>0 (0.00)</td>
<td>1 (3.00)</td>
<td>13 (21.70)</td>
<td>14 (11.40)</td>
</tr>
<tr>
<td>Cystic</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>9 (15.00)</td>
<td>9 (7.30)</td>
</tr>
</tbody>
</table>

* significant difference was found in prevalence of BD among different asthma severity groups (P<0.05). BD, bronchial dilation.

Table 4 The incidence of mucoid impaction and other HRCT abnormalities among different asthma severities

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Mild asthma, n (%)</th>
<th>Moderate asthma, n (%)</th>
<th>Severe asthma, n (%)</th>
<th>Total, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mucoid impaction*</td>
<td>2 (6.70)</td>
<td>5 (15.20)</td>
<td>23 (38.30)</td>
<td>30 (24.40)</td>
</tr>
<tr>
<td>Emphysema*</td>
<td>1 (3.30)</td>
<td>0 (0.00)</td>
<td>26 (43.30)</td>
<td>27 (22.00)</td>
</tr>
<tr>
<td>Mosaic lung attenuation†</td>
<td>1 (3.30)</td>
<td>0 (0.00)</td>
<td>6 (10.00)</td>
<td>7 (5.70)</td>
</tr>
<tr>
<td>Atelectasis</td>
<td>0 (0.00)</td>
<td>0 (0.00)</td>
<td>2 (3.30)</td>
<td>2 (1.60)</td>
</tr>
</tbody>
</table>

* significant differences were found in prevalence of mucoid impaction and emphysema among different asthma severity groups (P<0.05). † no significant difference was found in incidence of mosaic lung attenuation among different asthma severity groups (P>0.05). HRCT, high-resolution computed tomography.

Enrolled patients were further divided into none (n=60), mild (n=40) and severe (n=33) bronchial dilation, and we found that patients with severe bronchial dilation had a longer asthma history (28.13±18.55, P<0.001, P=0.003), older age (51.30±10.70, P=0.022, P=0.006), and lower FEV₁ % (41.97±15.19, P<0.001, P<0.001) and ratio of forced expiratory volume to forced vital capacity (FEV₁/FVC) (48.01±9.55, P<0.001, P<0.001) compared with those in none and mild bronchial dilation, and a negative correlation was found between the extent of bronchial dilation and...
FEV₁% and FEV₁/FVC (r=−0.359, P=0.004; r=−0.266, P=0.035, respectively) (Tables 5,6). However, there were no significant differences in BMI or smoking history among the three groups, neither in age, FEV₁% or FEV₁/FVC between the latter two groups.

The involved regions of bronchial dilation in the lungs were given in Table 7, which demonstrated that bronchial dilation was predominant in the right upper lobe, followed by right middle lobe, left lingual, and left lower lobe, and cylindric bronchial dilation mostly involved right middle lobe, while cystic bronchial dilation mainly occurred in left lower lobe.

**Discussion**

Our study found a relatively high incidence of structural abnormalities in Chinese patients with asthma, and the incidences of bronchial wall thickening, bronchial dilation and emphysema were more common in severe asthma. Patients with severe bronchial dilation had a longer asthma history, older age and lower FEV₁, compared with none and mild types, and a negative correlation was found between the extent of bronchial dilation and pulmonary functions.

Increasing evidence has demonstrated that asthma is an airway disorder with both structural and functional abnormalities, although the structural changes are obscure and not visible on routine chest X-rays. HRCT is a more sensitive tool, which can provide much morphologic information of the lungs and has been widely used in asthma study in recent years. A large variety of structural abnormalities in patients with asthma have been reported in HRCT, which mainly include bronchial wall thickening, bronchial dilatation, mucus impaction, air trapping on expiratory CT scans, small centrilobular opacities emphysema, and mosaic perfusion (14). However, there is no clear consensus about the ongoing role of HRCT in routine management of asthma patients or in clinical research in this area.

Bronchial wall thickening is a common abnormality in HRCT in asthmatics, but the prevalence varies in different studies (7,14,40,41). Up to date, there are no recognized diagnostic criteria for bronchial wall thickening (7). Paganin (14), Lynch (41) and Carr (40) reported that the prevalence

**Table 5** Baseline characteristics in patients with different types of bronchial dilation

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Non-BD (n=60)</th>
<th>Cylindric BD (n=40)</th>
<th>Varicose and cystic BD (n=23)</th>
<th>P (non-BD vs. cylindrical BD)</th>
<th>P (non-BD vs. varicose and cystic BD)</th>
<th>P(cylindric vs. varicose and cystic BD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (female/male)</td>
<td>39/21</td>
<td>28/12</td>
<td>17/6</td>
<td>0.602</td>
<td>0.438</td>
<td>0.741</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>23.9±3.58</td>
<td>23.78±3.39</td>
<td>23.01±3.14</td>
<td>0.831</td>
<td>0.285</td>
<td>0.380</td>
</tr>
<tr>
<td>Age (yrs)</td>
<td>44.70±11.81</td>
<td>42.43±12.45</td>
<td>51.30±10.70</td>
<td>0.358</td>
<td>0.022</td>
<td>0.006</td>
</tr>
<tr>
<td>Disease duration (yrs)</td>
<td>13.45±13.48</td>
<td>15.03±14.49</td>
<td>28.13±18.55</td>
<td>0.580</td>
<td>&lt;0.001</td>
<td>0.003</td>
</tr>
<tr>
<td>Smoking population (n)</td>
<td>10 (16.7%)</td>
<td>7 (17.5%)</td>
<td>3 (13.0%)</td>
<td>0.913</td>
<td>1.000</td>
<td>0.734</td>
</tr>
<tr>
<td>Smoking history (pack-years)</td>
<td>2.95±8.77</td>
<td>1.98±5.18</td>
<td>2.39±7.05</td>
<td>0.528</td>
<td>0.785</td>
<td>0.789</td>
</tr>
<tr>
<td>FEV₁% (%)</td>
<td>65.79±22.55</td>
<td>64.89±27.04</td>
<td>41.97±15.19</td>
<td>0.857</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FEV₁/FVC (%)</td>
<td>63.60±14.94</td>
<td>63.54±15.30</td>
<td>48.01±9.55</td>
<td>0.984</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

BD, bronchial dilation; yrs, years; BMI, body mass index; FEV₁%, predicted percentage of forced expiratory volume in one second; FEV₁/FVC, ratio of forced expiratory volume in one second to forced vital capacity; NS, not significant.

![Figure 4](image_url) The incidence of patients with different number of abnormal HRCT findings. Percentage of patients with normal HRCT is showed in bar A, and bar B to F represent one to five abnormal manifestations of HRCT, respectively. HRCT, high-resolution computed tomography.
of bronchial wall thickening was 16%, 92% and 62.5% respectively, and the latter two also concluded that the prevalence of bronchial wall thickening was significantly higher in asthmatics than in healthy subjects. Furthermore, Carr (40) discovered that the prevalence of bronchial wall thickening was higher in moderate asthmatics than in mild and moderate asthmatics. Harmanci and colleagues (15) found that bronchial wall thickening was present in bronchi not less than 1 mm, and the prevalence of bronchial wall thickening was 67.9%. They also found a positive correlation of bronchial wall thickening with disease severity in asthma and an inverse correlation with FEV₁. Our study adopted Harmanci’s criterion and found that the incidence of bronchial wall thickening was 57.7%, which was much higher in severe asthma. The differences in reported prevalence of bronchial wall thickening may be due to different methods, the number of studied bronchi, the status of the patients, and the set of the window level. The pathogenesis of bronchial wall thickening may be airway remodeling, namely subepithelial fibrosis, hypertrophy of the smooth muscle cell, mucus gland hyperplasia, and angiogenesis. Otherwise some reversible elements such as chronic airway inflammation and edema may play roles (15,33). Whether or not the structural changes such as subepithelial fibrosis, hypertrophy of the smooth muscle cell are reversible is still controversial (6,14,15,33).

Although radiation dose is an important problem, HRCT is treated as a noninvasive diagnosis tool to accurately detect bronchial dilation. Lynch and colleagues (41) found that 77% of asthmatic subjects had at least one bronchus larger than the accompanying pulmonary artery. The widely accepted diagnostic criteria for bronchial dilation are internal diameter greater than adjacent pulmonary artery or lack of tapering or visibility of peripheral airways. According to these criteria, the prevalence of bronchial dilatation in asthmatic patients has been reported to be 3% to 66.7% (40,42). Bronchial dilation can also occur in healthy subjects, but the prevalence has been reported to be much lower than that in asthmatic subjects (28,30,41,43). Cylindrical bronchial dilation was reported to be the most common morphologic pattern identified on CT scans of asthmatics, mainly involved in segmental and distal bronchi, especially in the lower lobes (14,15,43). Varicose and cystic bronchial dilation were rare, and they were observed mainly in the patients with the most severe asthma, while cylindrical bronchiectasis could be found in nearly all asthmatic patients (14,15). Some investigators reported that bronchial dilation was correlated with disease severity in asthma, FEV₁, and duration of asthma (15,30,44,45), and contributed to disease severity and difficulty of asthma control (42) but other studies haven’t found this correlation (14,28,40,41). Bronchial dilation is an irreversible change due to bronchial wall weakening and increased pressure in airways. Airway inflammation could undermine the integrity of the bronchial wall, and airflow limitation and air trapping could increase the pressure in airways. A balance between matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) may control the remodeling of extracellular matrix, and excessive MMPs expression may be associated with destruction or dilatation of airways in patients with asthma (30). One study reported that sputum elastase and metalloproteinase-9/tissue-inhibitor metalloproteinase-1 ratio were associated with

### Table 6 The correlation between the extent of bronchial dilation and spirometric parameters

<table>
<thead>
<tr>
<th>Parameters</th>
<th>FEV₁ (%)</th>
<th>FEV₁/FVC (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extent of BD</td>
<td>r</td>
<td>−0.359</td>
</tr>
<tr>
<td></td>
<td>P</td>
<td>0.004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>−0.266</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.035</td>
</tr>
</tbody>
</table>

BD, bronchial dilation; FEV₁%, predicted percentage of forced expiratory volume in one second; FEV₁/FVC, ratio of forced expiratory volume in one second to forced vital capacity.

### Table 7 The distribution of bronchial dilation in different lung lobes

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Right upper lobe</th>
<th>Right middle lobe</th>
<th>Right lower lobe</th>
<th>Left upper lobe</th>
<th>Lingual lobe</th>
<th>Left lower lobe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cylindric BD</td>
<td>24</td>
<td>30</td>
<td>16</td>
<td>13</td>
<td>24</td>
<td>19</td>
</tr>
<tr>
<td>Varicose BD</td>
<td>5</td>
<td>3</td>
<td>0</td>
<td>2</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Cystic BD</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>8</td>
</tr>
<tr>
<td>Total</td>
<td>30</td>
<td>33</td>
<td>19</td>
<td>17</td>
<td>29</td>
<td>30</td>
</tr>
</tbody>
</table>

BD, bronchial dilation.
the magnitude of abnormalities in the airways (including bronchial wall thickening and bronchial dilatation) on HRCT (46). In the study by Takemura and colleagues (30), 23 asthmatic subjects and 2 control subjects presented at least one dilated bronchus on HRCT sans, but they did not find the imbalance of MMP-9 and TIMP-1 to be related to bronchiectasis in asthma. They suspected that the negative result might result from the influence of inhaled corticosteroid therapy on the levels of MMP-9 and TIMP-1. Another explanation was that pulmonary artery diameter may be affected by blood volume or local hypoxia, thus affecting the identification of bronchiectasis. The exact causal relationship between bronchiectasis and asthma has not been fully understood. In the clinical setting, there are indeed some patients who are definitely diagnosed as bronchiectasis but manifest airway hyperresponsiveness or even typical wheeze. In this study, the enrolled asthma patients didn’t manifest typical symptoms of bronchiectasis such as sputum expectoration, hemoptyisis, and recurrent airway infection. Therefore we considered that bronchial dilation/bronchiectasis of these subjects might be ascribed to airway inflammation and consequent tissue destruction caused by asthma itself, namely a complication of asthma. Considering the fact that bronchiectasis was first listed as a complication of COPD in the GOLD document renewed in 2014, it is not a wild speculation that bronchiectasis may be a comorbidity of asthma. Whether or not the bronchiectasis should be included in the diagnosis of asthma is another question.

Mucus impactions have been found mainly in patients with severe asthma, but rarely found in mild and moderate asthma (14,15,47), and the incidence varied from 1.8% to 21.1% (14,15,33,36,38,47). Mucus impactions are reversible and could thoroughly disappear after therapy (14,33). In our study, the prevalence of mucus impactions was 22%, which was higher than that reported previously. We consider that it may be attributed to more severe asthma patients in our study and most patients not receiving regular therapy.

In previous studies, the prevalence of emphysematous changes in asthma ranged from 15% to 39% (15), while it was reported to be 24.4% in our study. We found that most of the asthmatics presented centrlobular emphysema, which was consistent with other studies (14,15,41). Emphysema was found to be closely related to smoking history, though it is also presented in nonsmoking asthmatics (41). Paganin (44) found that emphysema was significantly associated with the severity of disease. Park (9) revealed that asthmatics with emphysema tend to have a longer duration with asthma and severer airway obstruction. However, Harmanci (15) didn’t find such a relationship. Generally, emphysema is an irreversible change (14,15,31,33). Paganin (14) speculated that emphysema in asthmatics revealed by CT scan might not be explained by parenchymal destruction such as COPD. Extensive peribronchial fibrosis might be a culprit of cicatrinal emphysema.

Mosaic pattern of attenuation with patchy areas of increased and decreased attenuation is nonspecific and may be seen on HRCT scans in various infiltrating lung, airway, or vascular diseases or even healthy subjects (48). Prevalence of mosaic pattern of attenuation in asthmatics ranged from 3% to 18% (9,28,47). In the current study, mosaic pattern of attenuation was presented only in 7 asthmatics (5.7%), of which 6 were severe asthma. Park and colleagues (9) found that asthmatics presented with mosaic pattern of attenuation had a longer duration with asthma and severer airway obstruction, but Park (28) didn’t find the correlation between the presence of mosaic pattern of attenuation and FEV1%. It is believed that mosaic patterns results from reflective vasoconstriction secondary to hypoventilation of alveoli distal to airway obstruction and blood flow redistribution to adjacent normal areas of lung (38,48).

Limitations for our study included: (I) lack of data of medication duration and adherence especially the inhaled corticosteroids before enrollment, which may result in potential bias in selecting patients; (II) lack of inflammatory profile information, which may limit the implication and interpretation of our study results in different asthma phenotypes; (III) lack of HRCT radiation dose record even though a median radiation dose of CTDI of 7.87 mGyL and DLP of 281 mGycm being provided in our informed consent, which may lead to further restrictions on application of HRCT in patients with asthma; and (IV) manual examination of bronchial wall thickness rather than using automated computer software, as well as lack of control subjects for comparison, which may affect the accuracy of our study data because tangential cuts of airways and measurement of airway wall in a perpendicular to tubular plane could not be guaranteed.

Conclusions

In summary, our study provided further evidence that asthma is not only a functional but also a structural disease. The incidences of structural abnormalities detected by HRCT are fairly high in Chinese asthma populations, especially the bronchial wall thickening and bronchial dilation, which are significantly increased in severe asthma,
and are potential risk factors of pulmonary function decline in asthmatics.

Acknowledgements

We thank Professor Dongtao Lin (College of Foreign Languages, Sichuan University), who is specialized in biomedical writing and editing, for copyediting this manuscript.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: Our study protocol had been approved by the Institutional Ethics Committee Board of Clinical and Biomedical Research, West China Hospital (NO. 14004163), and all participants were provided written informed consent.

References

12. Sciurba FC. Physiologic similarities and differences between COPD and asthma. Chest 2004;126:117S-124S; discussion 159S-161S.


